
Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report) – Investment analysts at HC Wainwright increased their Q4 2026 earnings estimates for shares of Sutro Biopharma in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($1.93) for the quarter, up from their previous estimate of ($2.46). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($8.12) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q3 2027 earnings at ($2.41) EPS, Q4 2027 earnings at ($2.67) EPS, FY2027 earnings at ($9.24) EPS, FY2028 earnings at ($10.87) EPS, FY2029 earnings at ($7.59) EPS and FY2030 earnings at ($7.83) EPS.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($1.64) by ($0.26). The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $14.11 million.
A number of other equities analysts also recently issued reports on the company. Stifel Nicolaus set a $48.00 target price on Sutro Biopharma and gave the stock a “buy” rating in a research note on Friday, August 7th. Wedbush reissued an “outperform” rating and issued a $60.00 price target on shares of Sutro Biopharma in a report on Thursday, October 15th. Barclays lifted their price target on Sutro Biopharma from $56.00 to $57.00 and gave the company an “overweight” rating in a research note on Friday. Wells Fargo & Company began coverage on Sutro Biopharma in a report on Wednesday, September 30th. They set an “overweight” rating and a $49.00 price objective on the stock. Finally, Citizens Jmp cut their price objective on Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating for the company in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $49.60.
Read Our Latest Stock Report on Sutro Biopharma
Sutro Biopharma Trading Down 5.1%
Shares of STRO opened at $9.32 on Tuesday. Sutro Biopharma has a twelve month low of $7.15 and a twelve month high of $43.85. The stock’s 50 day moving average is $12.96 and its two-hundred day moving average is $22.51. The firm has a market capitalization of $154.53 million, a PE ratio of -0.78 and a beta of 1.56.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP acquired a new stake in shares of Sutro Biopharma during the 2nd quarter valued at approximately $359,000. Sigma Planning Corp acquired a new position in Sutro Biopharma during the first quarter worth $312,000. Jump Financial LLC purchased a new stake in Sutro Biopharma during the third quarter worth $208,000. Bank of America Corp DE boosted its position in Sutro Biopharma by 348.1% during the first quarter. Bank of America Corp DE now owns 18,873 shares of the company’s stock worth $470,000 after purchasing an additional 14,661 shares in the last quarter. Finally, Stempoint Capital LP acquired a new stake in Sutro Biopharma in the first quarter valued at $580,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.
More Sutro Biopharma News
These are some of the STRO news items that stood out recently:
- Positive Sentiment: HC Wainwright raised its price target to $57 and maintained a Buy rating, a potentially supportive signal for the shares. Sutro Biopharma Price Target Raised to $57.00
- Positive Sentiment: HC Wainwright improved its Q4 2026 EPS estimate to a loss of $1.93 per share from a previously forecast loss of $2.46, indicating a less pessimistic near-term outlook.
- Negative Sentiment: HC Wainwright cut its full-year EPS forecasts for 2027–2030, projecting larger losses: $9.24 per share for 2027, $10.87 for 2028, $7.59 for 2029 and $7.83 for 2030. These deeper projected losses may temper the positive impact of the target increase.
About Sutro Biopharma
Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.
See Also
- Five stocks we like better than Sutro Biopharma
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
